The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies

Muscular Dystrophies Clinical Trial

Official title:

Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00674843
• Other study ID #: GAAD-MD-CTP1
• Status: Active, not recruiting
• Phase: Phase 1
• First received: May 6, 2008
• Last updated: August 14, 2009
• Start date: May 2008
• Est. completion date: June 2010

Study information

• Verified date: August 2009
• Source: GAAD Medical Research Institute Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The muscular dystrophies (MD) are a group of more than 30 neuromuscular disorders that are characterized by progressive skeletal muscle weakness, defects in muscle proteins and the death of muscle cells and tissue. This study will investigate the use of far infrared radiation for managing muscular dystrophies.

Description:

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly cure these neuromuscular disorders.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 4
• Est. completion date: June 2010
• Est. primary completion date: May 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Persons with muscular dystrophies

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Muscular Dystrophies

Intervention

Radiation:
• Far Infrared Radiation
Radiation: Far Infrared Radiation (5µm to 20µm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.

Locations

Country	Name	City	State
Canada	The Centre for Incurable Diseases	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
GAAD Medical Research Institute Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Management and Cure of muscular dystrophies		2 Years	No
Secondary	Rehabilitation of people with muscular dystrophies		2 Years	No